Company intelligence
EIGEN Bio
Decoding cellular regulation into actionable drug insights
Biotechnology Research
San Francisco, US
8 employees
5 public signals
About EIGEN Bio
EiEigen Bio is a causal therapeutic intelligence platform that uses RNA, perturbational biology, and AI to understand disease mechanisms, identify actionable therapeutic opportunities, and accelerate better decisions from discovery through clinical development.
Verified activity
Signals from EIGEN Bio
5 published signals
Presence & Recognition
EIGEN Bio collaborated with Dr. Van Morris and the MD Anderson Cancer Center team to answer the question of understanding biological transitions in MSS and BRAF V600E metastatic colorectal cancer for presentation at ESMO 2026.
Reported by EIGEN Bio
Presence & Recognition
EIGEN Bio's work with Dr. Van Morris and the team at The University of Texas MD Anderson Cancer Center has been accepted for presentation at ESMO - European Society for Medical Oncology 2026
Reported by EIGEN Bio
Presence & Recognition
EIGEN Bio is attending the HLTHUSA conference.
Reported by EIGEN Bio
Research & Knowledge
EIGEN Bio is working on integrating human molecular data, perturbation experiments, and mechanistic relationships across biological systems to inform drug discovery decisions.
Reported by EIGEN Bio
Research & Knowledge
EIGEN Bio spoke with leaders working with AI across public companies, venture firms, and high-growth startups to understand where speed helps, where it hurts, and what changes when work becomes dramatically easier to produce.
Reported by Kristin Gleitsman